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Accurate single cell mutational profiles can reveal genomic cell-to-cell heterogeneity. How-
ever, sequencing libraries suitable for genotyping require whole genome amplification, which
introduces allelic bias and copy errors. The resulting data violates assumptions of variant
callers developed for bulk sequencing. Thus, only dedicated models accounting for amplifi-
cation bias and errors can provide accurate calls. We present ProSolo for calling single
nucleotide variants from multiple displacement amplified (MDA) single cell DNA sequencing
data. ProSolo probabilistically models a single cell jointly with a bulk sequencing sample and
integrates all relevant MDA biases in a site-specific and scalable—because computationally
efficient—manner. This achieves a higher accuracy in calling and genotyping single nucleotide
variants in single cells in comparison to state-of-the-art tools and supports imputation of
insufficiently covered genotypes, when downstream tools cannot handle missing data.
Moreover, ProSolo implements the first approach to control the false discovery rate reliably
and flexibly. ProSolo is implemented in an extendable framework, with code and usage at:
https://github.com/prosolo/prosolo
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Originally, genome sequences have been queried for geneticgermline variation or for highly abundant somatic var-iation, for example in cancer. The advent of high-
throughput single-cell sequencing has recently turned the spot-
light on a type of so far understudied variation: the often less
abundant somatic or post-zygotic variation that constantly
accumulates with every mitotic cell division throughout the life-
time of an organism, turning every individual into a complicated
genomic mosaic1. Estimates for somatic single nucleotide variants
(SNVs) range from around 0.6 × 10−9 up to 60 × 10−9 mutations
per genome position per cell division2–5, with a recent estimate6
based on single-cell sequencing at 2.66 × 10−9. With the size of
the human (reference) genome at ~3.2 × 109 base pairs, these
numbers indicate that even during healthy development, most
cells harbor cell-specific point mutations. This enables retro-
spective monitoring of lineages involved in normal organism
development, merely by sampling some cells7, without having to
interfere with its general development or having to kill the
individual. In other words, this establishes a universally applicable
methodology for in vivo lineage tracing.
In cancer development, this variation can be used to trace the
cellular ancestry of tumor subclones and metastases8–11, and to
characterize the evolutionary dynamics of cancer
progression12,13. In the long run, methods that account for the
dynamics of mutational signatures in cellular evolution will
improve the diagnosis, treatment, and prognosis of diseases for
which somatic alterations are a key factor. To this end, obtaining
accurate profiles of the genetic variation affecting single cells is
essential.
In sequencing libraries prepared directly from single cells, only
a small fraction of the genome is sampled. To obtain coverage
levels that allow for the consistent identification of SNVs across
larger parts of the genome, in vitro whole genome amplification is
crucial. Among whole genome amplification methods, multiple
displacement amplification (MDA14) has proven the least error-
prone and is therefore considered the state-of-the-art in single-
cell SNV profiling15–18. But, although the type of polymerase used
in MDA (Φ29) has the highest fidelity currently attainable (due to
its proof-reading functionality), amplification errors still occur at
a rate of 1.24 × 10−6 to 9.5 × 10−6 per copied base15,19–22—three
orders of magnitude higher than the estimates for the somatic
mutation rate. Further, the efficiency and fidelity of Φ29 poly-
merase depends on the template sequence context23, implying
that the amplification error rate systematically varies around this
average. Moreover, the degree of amplification depends on the
quality of the template DNA extracted from the single cell24 and
how accessible each stretch of DNA is to amplification initiation
via priming25. As a result, sequencing coverage after amplification
differs both between sites along the genome and between the two
alleles at a particular site, up to the entire dropout of alleles26.
Because standard variant callers assume that alleles are uniformly
covered, they do not perform well on the resulting data and are
substantially outperformed by single-cell variant callers27,28.
Clearly, when calling SNVs for single cells, the statistical uncer-
tainties introduced by the amplification need to be dealt with at
the largest possible accuracy.
Thus, variant callers for whole genome-amplified single-cell
data need to account for both amplification errors and allelic bias,
in addition to accounting for the site-specific variation. However,
state-of-the-art single-cell SNV callers routinely assume fixed
global rates when modeling uneven allelic coverage (up to
dropout) and amplification errors. For example, to reflect the
amplification error rate, both MonoVar27 and SCcaller28 work
with global false-positive error rates for calling the presence of an
alternative allele at a particular site. This assumes that Φ29
polymerase is agnostic to local template sequence context,
although it is not23. Similarly, for modeling allele dropout,
MonoVar27 and SCIPhI29 assume that one rate applies globally
(and across all cells). This neglects that allele dropout, as the
extreme case of uneven allele coverage, varies greatly along the
genome and in particular also between cells, because their DNA is
amplified separately. Interestingly, SCIPhI29 additionally models
allelic amplification bias to be governed by one global beta-
binomial distribution (to apply for all cells in a dataset), thereby
accounting for allelic dropout a second time (as the extreme
values at 0 and 1 of that distribution). Two tools that more
variably model allelic amplification bias are SCcaller28 and
SCAN-SNV30. Both estimate the minor allele frequency from
nearby germline heterozygous sites. However, SCcaller employs a
fixed global false-positive error rate for the calling of alternative
alleles28, and SCAN-SNV makes use of heuristics for filtering
candidate variants30. Thus, to the best of our knowledge, there is
no statistical model that allows for both local variation of bias and
errors due to amplification, and for statistically sound false dis-
covery rate control when calling and genotyping SNVs in
single cells.
In this work we describe ProSolo, a variant caller using a
unifying statistical framework that takes into account all relevant
MDA-related biases and errors, allowing for them to vary locally.
Importantly, our model enables a scalable—because computa-
tionally efficient—implementation, which is challenging even in
bulk variant calling when considering local effects due to statis-
tical uncertainties affecting the data31. ProSolo’s statistical rigor
allows for accurate control of the false discovery rate when calling
alternative alleles or identifying other relevant effects, such as
allele dropout. It achieves a higher variant calling accuracy
compared to state-of-the-art tools.
Results
Comprehensive and flexible single-cell sequencing model. We
describe a probabilistic model that addresses the genotyping of
diploid single cells whose DNA has been subject to whole genome
multiple displacement amplification (MDA)14. Here, we name the
central innovations of our model and demonstrate its advantages
in comparison to existing approaches. A more detailed descrip-
tion of the innovations is available in the Methods section.
Briefly, our model addresses the two major issues of MDA: (i)
the differential amplification of the two alleles present in a diploid
cell (“amplification bias” in the following); (ii) MDA induced
errors (“amplification errors” in the following) which are copy
errors introduced by the Φ29 polymerase used in MDA. To
address amplification bias, we leverage a mechanistically
motivated, empirically derived model of differential amplification
of alleles. To assess amplification errors, we evaluate single-cell
samples together with a bulk sample from which the single cell is
supposed to stem. Regarding the latter, we argue that a bulk
sample should be added to single-cell sequencing experiments
wherever possible: it samples from the same cell population
without requiring amplification, and is therefore unaffected by
amplification bias and errors and thus makes a particularly useful
background sample to address the statistical uncertainties and
biases induced by MDA. At the same time, one of the major
features of the core model and its implementation is that it can
easily be adapted to flexibly deal with other sampling setups, so it
could be extended to further scenarios.
Consistently high alternative allele calling accuracy. The most
precise single-cell variant callers to date, SCcaller and SCIPhI,
only call the presence vs. the absence of an alternative allele (i.e.,
the heterozygous and the homozygous alternative genotypes
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called jointly). We thus focused on this for the main
benchmarking.
The whole genome cell line dataset (see below, Methods
section) seems much less challenging than the other dataset, as all
methods achieved very high precision in alternative allele calling
(Fig. 1a and Supplementary Fig. 7a), at recall rates of 0.45 and
higher. In comparison to all other tools, ProSolo shows striking
increases in the recall. For example, an increase of nearly 10% for
precision above 0.99, where its maximum recall is 0.766,
compared to 0.705 for MonoVar, 0.687 for SCIPhI, and 0.610
for SCcaller. The only exception with a recall of 0.0001 is SCAN-
SNV (at a precision of 0.992). This can be explained by it aiming
at somatic mutations, while the vast majority of SNVs in a
genome will be germline variants.
Although a relative increase in recall of about 10% at utmost
precision is certainly remarkable, ProSolo demonstrates its power
on the second (whole exome) dataset (see below, Methods
section). For this dataset, only SCcaller, SCIPhI, and ProSolo
achieved a precision above 0.99, with ProSolo reaching a 20%
increase of recall to 0.178, compared to SCIPhI’s 0.146, and
SCcaller with 0.072 (Fig. 1b and Supplementary Fig. 7b). In
comparison, MonoVar achieved a maximum precision of only
0.962. However, this was at a much higher recall (0.141) than for
example SCcaller (0.095 at a precision of 0.972). SCcaller’s
decreased recall on this dataset might be due to its estimation of
local allelic bias by also taking biases at neighboring sites into
account—in whole-exome data the number of neighboring sites
available for this estimation will be limited and might lead to less
reliable estimates.
On this dataset, SCAN-SNV’s recall increased to 0.0016 at a
decreased maximum precision of 0.897. Most likely, this
decreased precision is an artifact of using the germline genotype
as ground truth. At the sites with somatic mutations in single
cells, which SCAN-SNV focuses on, this ground truth will instead
contain the homozygous reference germline genotype and will
incorrectly classify (existing) alternative alleles as false positives.
Due to this effect, we also expect the calculated precision of all the
other tools to be underestimated. However, as the other tools also
Fig. 1 Precision-recall plots for alternative allele calls of ProSolo, MonoVar, SCAN-SNV, SCcaller, and SCIPhI. All panels are strong zoom-ins, focusing
on (different) areas of interest. Global views of these panels are provided in Supplementary Fig. 7. a Precision and recall of an average of two whole
genome sequenced single cells IL-11 and IL-12 against their kindred clone IL-1C as ground truth genotypes. b Precision and recall average of the five whole-
exome sequenced single granulocytes against their pedigree-based germline genotype ground truth. c Precision and recall average of 16 tumor and 16
normal single cells sequenced at the whole exome level. −b The germline ground truth induces an artificial increase of recall for SCIPhI’s sensitive and
ProSolo’s imputation mode; these modes should thus be disregarded for a fair comparison on the granulocyte dataset in panel b. Threshold parameters
(not comparable across tools): MonoVar --t; ProSolo --fdr; SCAN-SNV --fdr; SCcaller -a cutoff; SCIPhI prosolo --fdr. Software modes: MonoVar with
consensus filtering (default) or without (no consensus); ProSolo with minimum coverage 1 in single-cell (default), or imputing zero coverage sites based on
bulk sample (imputation); SCcaller with recommended settings (default) or with a more sensitive calling; SCIPhI with default parameters (default) or all
heuristics off (sensitive).
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provide alternative allele calls for all sites where the single cells
retained this germline genotype, the relative effect on their
precision will be smaller.
At the same time, this germline ground truth caveat also
indicates that the recall of SCIPhI’s sensitive mode and ProSolo’s
imputation mode will be an overestimate. Whenever coverage of
a site is missing in a single cell, SCIPhI may impute the genotype
with the last common ancestor genotype of the most closely
related cells, while ProSolo will impute to the majority genotype
in the bulk sample. Both strategies provide a biologically
meaningful imputation that will be more useful than post hoc
modes of imputation. However, at single-cell sites where a
somatic mutation has created a true alternative allele, but no
coverage is provided, we expect that both methods are most likely
to call the homozygous reference germline genotype. In then
comparing this to the germline genotype as the ground truth,
these calls will be classified as true negatives even though they
really constitute false negatives, thus artificially increasing recall.
While the underestimation of precision equally affects all tools
and generally means that benchmarking results are more
conservative than with a more accurate (somatic) ground truth,
this overestimation of recall in only these modes of two tools does
not allow for a fair comparison. We have thus excluded both
SCIPhI’s sensitive mode and ProSolo’s imputation mode from the
discussion of the whole exome dataset with its germline ground
truth (but their results are nevertheless displayed in Fig. 1b and
Supplementary Figs. 7b, 9 for reference).
For the third dataset of single nucleus whole-exome sequencing
data of 32 cells from a TNBC patient (16 tumor cells and 16
normal cells), we analysed tumor and normal cells separately
(Fig. 1c). On the tumor cells, ProSolo is the only tool to achieve a
precision above 0.99 (at a recall of 0.319). On the normal cells,
both ProSolo and SCIPhI achieve a precision above 0.99. Here,
SCIPhI outcompetes ProSolo with a maximum recall of 0.650
compared to ProSolo’s 0.548. While ProSolo can achieve a similar
recall (0.625, see –fdr threshold of 0.2 in Supplementary Fig. 7c),
this comes at a reduced precision. This reflects the inherent
uncertainty of the single-cell data and showcases a key difference
in the approaches of ProSolo and SCIPhI. Where ProSolo models
each cell and each genomic site separately, SCIPhI’s model
integrates information across all sites in all cells at once. While
this can clearly help recover recall, this can also lead to false-
positive somatic variant calls (Supplementary Fig. 13) and has
clear implications for model complexity and software runtime. As
all other tools, including ProSolo, are parallelizable over genomic
regions and were thus able to process both datasets within days
on a multicore machine, we do not report more detailed runtimes
for them. However, it should be noted that SCIPhI took from
1 week (with iterations reduced below software defaults) on the
single nucleus whole-exome dataset up to 7.5 weeks on the whole
genome dataset, running on a single core without any possibility
of parallelization. And where adding breadth of coverage (i.e.,
more genomic sites) or more cells simply means adding more
parallel processes in most tools, both will further increase
SCIPhI’s wall time. In addition, adding more cells grows the
space of possible tree topologies that SCIPhI explores super-
exponentially13, which will further increase its runtime.
Flexible control over the false discovery rate. Finally, a feature
where ProSolo clearly stands out is the control over the false
discovery rate. As can be seen in Fig. 1 (and Supplementary
Fig. 7), ProSolo provides flexible control over precision vs. recall
via specifying a false discovery rate of interest and is the only tool
to achieve a precision of over 0.99 on the single tumor cell
datasets from Wang et al.21. While no other tool provides a
formal control over the easily interpretable false discovery rate,
several of the tools provide other types of thresholds that we
varied in attempts to achieve higher precision or recall. However,
none of them provide control over similar ranges of precision and
recall. In addition, we ran the standard false discovery rate control
implemented in ProSolo on the posterior probabilities provided
by SCIPhI, but this did not provide any substantial control over
the false discovery rate (Fig. 1 and Supplementary Fig. 14). The
only limit to that range with ProSolo’s current model is that it
becomes less accurate when controlling for very small false dis-
covery rates (below 0.01% for alternative allele calling in the
whole genome dataset, see Supplement Supplementary Sec-
tion 2.6). But this still leaves ProSolo as the only tool that pro-
vides the user with the choice of either aiming for more
discoveries at the cost of a higher rate of false discoveries, or at
aiming for a more limited number of discoveries with higher
confidence in each of them.
Valid model estimates of the allele dropout rate. Leveraging our
ground truths and using three different ways to calculate the allele
dropout rate, we can confirm the general validity of our single-cell
event definitions and also explore the limitations of the current
model (Methods section). The expected allele dropout rates based
on the ProSolo probabilities for allele dropout clearly fall into the
range of previously published allele dropout rates21,22,26,32–36
(“published” in Fig. 2). This analysis also clearly shows that the
ProSolo expected allele dropout rates, based on the model’s
probabilities, correspond to those determined by comparing
ProSolo genotypes with the ground truth (Fig. 2). This demon-
strates that the explicit modeling of allele dropout events works
and is useful for genotyping. However, in that comparison, the
expected allele dropout rate was consistently underestimated on
our own whole-exome data (“granulocytes”, Fig. 2), and slightly
overestimated for the data from Dong et al.28 (“Dong 2017”,
Fig. 2). The comparison to a naively calculated allele dropout rate
consistently shows an overestimation of the allele dropout
probability, which is strongest for the samples with higher overall
coverage (IL-11, PAG1, PAG10, Fig. 2 and Supplementary Fig. 3).
However, this overestimation of the allele dropout probability
does not seem to impact the genotyping resolution (Supple-
mentary Figs. 15 and 16).
Discussion
ProSolo is the first method for SNV calling from MDA single-cell
sequencing data to comprehensively model both amplification
bias and amplification errors in a way that enables both the
integration of site-specific differences (Fig. 3), and a computa-
tionally efficient—hence practically scalable—evaluation of all
relevant data properties. We achieve this by combining a data-
driven model of amplification errors (that incorporates a bulk
background sample alongside the single-cell sample) with an
empirical model of amplification bias which is dependent upon a
site’s coverage (and is based on a statistical understanding of the
MDA process that is mechanistically motivated). The underlying
model calculates posterior probabilities for fine-grained single-cell
event definitions, whose false discovery rate can be controlled for
and that can pass more information about data uncertainties to
probabilistic models in downstream analyses; including methods
that can then use this reduced, but highly accurate, data repre-
sentation to integrate information across cells, for example for the
phylogenetic reconstruction of cell relationships. Importantly, the
calculation of posterior probabilities scales linearly in the cover-
age of variant sites, which is the fastest theoretically conceivable,
documented by runtimes that have substantial advantages over
the state-of-the-art in practice. Using one whole genome dataset
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Fig. 2 Concordance of three differently calculated per-cell (IL-1 and PAG cells) allele dropout rates across ground truth heterozygous sites, in the
context of allele dropout rates from the literature21,22,26,32–36. The expected value of the allele dropout events in ProSolo (dark gray) is concordant with
the number of false homozygous genotype calls made by ProSolo on those sites (black) and both values are well within the range of published allele
dropout rates for single-cell MDA sequencing data (“published”, to the right, very light gray). The naive allele dropout rate (light gray)—calculated as
ground truth heterozygous sites with a minimum coverage of seven and either no read with the reference allele or no read with the alternative allele
—-shows discrepancies with ProSolo’s estimates of allele dropout for samples with a more uniform coverage (IL-11, PAG1, PAG10, Supplementary Fig. 3).
Fig. 3 High-level overview of ProSolo’s variant calling model. a, b Exemplary alternative allele read count distributions for sites covered by 20 reads, as
derived by Lodato et al.22 Homozygous reference sites in a are assumed to follow a beta-binomial distribution; sites heterozygous for the alternative allele
in b are assumed to follow the linear combination of two symmetrical beta-binomial distributions (dotted and dashed lines). c Toy example of calling the
same genomic site in two single cells from the same population that differ in their true underlying allele frequencies for alternative allele C (blue, θs= 0 vs.
θs= 0.5). Alternative nucleotide T (orange) is an amplification error. Empirical distributions in A and B account for the amplification bias, and likelihoods for
the alternative allele candidates from the bulk reduce the likelihoods of amplification errors, thereby correctly identifying both the error and the original true
mutation. This is formalized with the model in D. d Definition of single-cell events based on ProSolo’s likelihood density estimates for the spectrum of true
underlying alternative allele frequencies in the single-cell (~θs) and the bulk (~θb). The bulk is always assumed to be a combination of a maximum of two
genotypes at a particular site, generating all possible θb (bottom panel). The model further assumes that the bulk sample has sufficient coverage to capture
somatic variants. ADO allele dropout, alt alternative, err error, het heterozygous, hom homozygous, ref reference.
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and two whole-exome datasets—each with a different type of
ground truth (Fig. 4)—we demonstrate that these two innovations
of ProSolo combine to achieve competing or better accuracy
(Fig. 1). Moreover, the model allows to accurately control the
false discovery rate of variant calls, another novelty of great
practical value, and both the model and its modular imple-
mentation are easy to adapt and extend.
Especially the joint modeling of a single cell and a bulk sample
is favorable from a statistical point of view: in terms of MDA
induced bias and errors, the bulk acts as an unbiased sample of
the population from which the single cell was drawn. Given
enough bulk coverage (Supplementary Fig. 13), this provides a
drastically more sensitive approach compared to, for example, the
consensus rule of calling alternative alleles only when there is
evidence in at least two (or even three) single cells (as imple-
mented in MonoVar27). A more systematic and biologically
relevant model of sharing information is implemented in SCIPhI,
where the phylogenetic relationship of cells is part of the esti-
mated parameters. Intuitively, if two cells are closely related, they
have a higher likelihood of sharing a genotype at a particular site.
However, both the consensus rule and the sharing of information
via an inferred phylogeny requires that more than one single cell
exhibit sufficient coverage of an alternative allele to call it reliably.
This will rarely be achieved in single-cell MDA experiments,
which are still often limited to a few dozen cells. In contrast, bulk
sequencing can easily be scaled to a much larger sampling of a cell
population—representing hundreds or thousands of cells of a cell
population—simply by adding a single higher coverage sample.
Our benchmarking experiments demonstrated that ProSolo, by
jointly modeling a single cell sample with a bulk sample, is the
only tool to consistently achieve a precision above 0.99. In almost
all datasets this precision is provided in concert with a sub-
stantially higher recall than any other tool. The only exception is
the normal cells dataset from the single nucleus exome sequen-
cing data, for which SCIPhI attains a higher recall above 0.99
precision—but at the cost of false-positive calls of subclonal
heterozygous variants (Supplementary Fig. 13), while lacking the
ability to call sites with a homozygous alternative genotype
(Supplementary Fig. 13). Interestingly, a bulk coverage as low as
4X already provides drastic performance improvements in Pro-
Solo’s model and allows for a meaningful control over the false
discovery rate (Supplementary Fig. 12; but higher bulk coverage
will be necessary to detect low-frequency somatic variants, Sup-
plementary Section 2.5). To summarize our benchmarking of
alternative allele calling: SCcaller seems optimized for precision,
MonoVar achieved higher recall than SCcaller, and SCAN-SNV
does not seem suitable for general variant calling on MDA single-
cell sequencing data but is only applicable when restricting
interest to somatic variants. ProSolo clearly achieves the best
precision. In two out of three datasets with fewer cells, this pre-
cision comes with a higher recall than in any other tool. This
demonstrates, that ProSolo’s model captures data from individual
single cells better than any of the existing models. Only in the
dataset with more cells and a bulk sample with lower coverage,
SCIPhI can reach a higher recall than ProSolo by integrating
information across cells (but at the cost of false-positive somatic
mutation calls). However, with default configuration, SCIPhI
takes weeks on a single core without any possibility of paralleli-
zation, compared to a runtime of only days on a cluster for all the
other tools. This is the result of the general approach, integrating
information across cells and across genomic sites all at once.
Thus, any addition of genomic coverage and cells will further
increase SCIPhI’s wall clock runtime, where adding cells could
prove especially troubling: adding cells will super-exponentially
grow the space of possible tree topologies to explore. Other tools,
including ProSolo, can simply add more parallel processes per site
and cell and can thus leverage cluster computing for larger
datasets, something that becomes more urgent with the advent of
scalable droplet-based single-cell whole genome amplification
methods13.
Jointly calling single-cell variants with a bulk background
sample also enables a biologically relevant imputation of geno-
types at sites where single cells lack coverage. If genotype profiles
without missing values are for example required by downstream
tools, ProSolo can provide a cell population-specific imputation
instead of resorting to a majority assignment (limited by the
number of single cells sequenced) or even imputation based on
external databases (e.g., dbsnp). However, any imputation will
usually favor germline genotypes over low-frequency somatic
genotypes (even though the opposite case also happens for SCI-
PhI, where some heterozygous subclonal variants are called in a
lot more cells than the ground truth suggests, Supplementary
Fig. 13). Thus, we suggest to not impute zero-coverage single cell
sites whenever possible and instead recommend using and
developing downstream software that can deal with both these
missing values and the event probabilities that ProSolo provides.
With this approach, uncertainties in the probabilities and infor-
mation about missing data are passed on and will allow for more
accurate statistical modeling in those downstream analyses.
Finally, ProSolo is the only method that provides a clearly
interpretable false discovery rate parameter that can actually
Fig. 4 Benchmark Datasets. For single cells, DNA was multiple
displacement amplified (MDA). a Whole genome sequencing (WGS)
dataset, generated from a clonal population started with an individual cell28,
and expanded further downstream to generate different bulk samples (C1,
C2, C3, and IL-1C). b Newly generated whole exome sequencing (WXS)
dataset of blood cells. Ground truth genotypes of patient CCS1 were
determined from sequencing data of family members (boxes male; circles
female). Granulocytes were isolated from blood using magnetic and
fluorescence-activated cell sorting (MACS and FACS). c Whole exome
sequencing (WXS) dataset from a triple-negative breast cancer (TNBC)
patient21. For tumor cells (a1 to a8 and h1 to h8), the cell population (pop)
sequencing of the normal sample was taken as the ground truth, including
known clonal tumor-specific somatic variants previously validated by deep
targeted duplex (td, dx) sequencing21. For normal cells (n1 to n16), the cell
population (pop) sequencing of the tumor sample was taken as the ground
truth, after removing known clonal and subclonal tumor-specific somatic
variants previously validated by deep targeted duplex (td, dx) sequencing21.
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control the trade-off between precision and recall (and this false
discovery rate is the only parameter any user will have to specify).
This can be used on alternative allele calls (Fig. 1, Supplement
Supplementary Section 2.6), the main focus of our benchmarking,
but also on any of the events pertinent to single-cell analysis (such
as allele dropout or amplification errors) or combinations thereof
(see Fig. 3d for all events). Thereby, beyond just calling alternative
allele presence in a statistically reliable way, ProSolo can, for
example, also compute the expected allele dropout rate across the
entire genome of a particular cell in a robust manner (Supple-
mentary Equation S 31 and Fig. 2).
ProSolo determines such global rates from its reliable site-
specific posterior probabilities for all single-cell events that might
be of interest, including allele-resolved genotypes, allele dropout,
or amplification errors. We anticipate that such fine-grained site-
specific probabilities—and the uncertainties they capture—will be
informative for improving probabilistic modeling in downstream
analyses. They could e.g., prove useful in models for phylogenetic
reconstruction of the lineage relationship of sequenced single
cells29,37,38, thus achieving reconstruction results similar to or
better than SCIPhI, while keeping the analyses modular and thus
computationally tractable13.
An in-depth look at one of the above-mentioned fine-grained
events, allele dropout, showed that ProSolo’s allele dropout rate
estimates were within the range of published estimates. This
confirms that our modeling of allele dropout events is realistic
and can be useful in alternative allele calling and genotyping.
However, the allele dropout rate estimations were slightly off in
different directions for the different benchmarking datasets,
suggesting that the empirical distributions we currently make use
of (based on Lodato et al.22) may not suit all datasets. For
example, the degree to which whole genome amplification
introduces variability may be dataset-specific, something not
currently captured in our model. This conclusion is further
supported by the naively calculated allele dropout rate, which is
much lower in the high coverage cells of the two datasets (IL-11
for the Dong et al. data28, PAG1, and PAG10 in our granulocytes;
see Supplementary Fig. 3). Interestingly, the sample IL-11 from
Dong et al.28 has been suggested to be a doublet30, which might
explain the higher overall coverage and points to a possible source
for the discrepancy between the naively calculated and the esti-
mated allele dropout rates. If samples PAG1 and PAG10 were
doublets as well, this would indicate that our use of empirical
distributions in ProSolo provides for more robust event prob-
abilities in the presence of doublets, while heuristic thresholding
(as in our naive allele dropout estimate) is very sensitive to such
perturbations.
In general, the use of a fixed empirical model for MDA allelic
bias does not seem to impede ProSolo’s performance in alter-
native allele calling compared to the other tools, but has a
noticeable effect on genotyping (Supplement, Supplementary
Section 2.8, and Supplementary Fig. 13) and might be responsible
for imprecisions when controlling for very small false discovery
rates (Supplement, Supplementary Section 2.6). When future
datasets are generated based on improved MDA protocols13,
these effects might be exacerbated. We, therefore, consider it
important for future work to improve on the fitting of the
empirical read count distributions observed when applying MDA
to single cells (Supplement, Supplementary Section 1.2.2). For
example, the parameters of the mechanistically motivated com-
bination of beta-binomial distributions for modeling hetero-
zygous genotypes could be learned per single cell sample at
germline heterozygous sites—similar to the approaches of
SCcaller and SCAN-SNV, but globally per cell with their local
variation modeled by their dependence on a site’s coverage.
In addition, the current model prevents the calling of subclonal
somatic mutations with a bulk sample that has insufficient cov-
erage to sample the respective allele, which can easily be remedied
by sequencing the bulk sample to a greater depth. In addition,
including a prior for the somatic mutation rate in the bulk sample
further improve recall. Newer versions of the Varlociraptor
library31 already allow using such a prior, so this is immediate
future work. When bulk coverage is low and an alternative allele
is not sampled by any read, the prior will result in nonzero
alternative allele frequencies in the bulk being assigned nonzero
likelihoods, which is the desired behavior for this constellation.
When bulk coverage is high, the increased amount of data will
progressively overrule the prior.
Further room for improvement also remains for the modeling
of the homozygous genotypes: while the current distributions
account for both amplification and sequencing errors, sequencing
errors are already safely accounted for elsewhere in our latent
variable model. Beyond low coverage in the bulk background
sample, this might be another reason why some subclonal somatic
heterozygous variants are misclassified as homozygous by Pro-
Solo (Supplement, Supplementary Fig. 13). Here, an amplification
error profile that is not compounded with sequencing errors
would need to be based on the Φ29 polymerase error rate and a
better understanding of the statistical distribution that these
errors generate (Supplement, Supplementary Section 1.2.2).
Studying and implementing the corresponding changes in the
future has the potential to further improve the accurate site-
specific event probabilities that ProSolo already provides through
the joint modeling with a (sufficiently deep) bulk background
sample.
Finally, the modular implementation of ProSolo within the
context of the Varlociraptor library31 facilitates the imple-
mentation of further features, such as read-backed phasing39,40 or
even more variable models of amplification bias30 that could be
integrated to exhaustively leverage MDA data information con-
tent. While no standardized software is available, it seems to be
possible to obtain copy number profiles from single cells41,42.
Extending our model to make use of such profiles, it should also
be possible to salvage cancer-related variant cases that our current
model setup does not capture (Supplement, Supplementary Sec-
tion 1.5.1). And since the Varlociraptor library also provides
advanced functionality for the calling of insertions, deletions and
multiple nucleotide variants (MNVs), one of the immediately
following next steps will be to adapt ProSolo to calling those in
single cells.
Overall, ProSolo provides an accurate and easy-to-use variant
caller for single-cell MDA sequencing data, which will easily scale
to calling variation on more cells and broader genomic coverage.
It will thus empower more research using single-cell DNA
sequencing data.
Methods
Single-cell sequencing model. Here, we introduce the central innovations of our
probabilistic model for genotyping of diploid single cells whose DNA has been
subject to whole genome multiple displacement amplification (MDA)14. More
details and a detailed derivation of all model elements can be found in the Sup-
plement, including a summary of the core model.
We address amplification bias by leveraging a mechanistically motivated,
empirically derived model of differential amplification of alleles and assess
amplification errors by evaluating single-cell samples together with a bulk sample
from which the single cell is supposed to stem. Regarding the latter, we argue that a
bulk sample should be added to single-cell sequencing experiments wherever
possible: it samples from the same cell population without requiring amplification,
and is therefore unaffected by amplification bias and errors and thus makes a
particularly useful background sample to address the statistical uncertainties and
biases induced by MDA. For related work on flexible bulk sequencing sample
composition, see Köster et al.31.
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A mechanistically motivated model of amplification bias, trained on data, gives
realistic coverage-specific single-cell (genotype) likelihoods. To account for MDA
amplification bias up to the complete dropout of individual alleles, we distinguish
between two alternative allele frequencies:
(i) The true (but usually unknown) underlying allele frequency at a site in a
single cell: θs. This can be assigned one of three possible values, namely
θs∈ {0, 0.5, 1}, where 0 and 1 represent the homozygous reference and
alternative genotype and 0.5 a heterozygous genotype. However, the ratio of
reads harboring the different alleles from a single cell sequencing
experiment does not reflect the true allele frequency, because of the biases
induced by amplification. Instead, the ratio of reads reflects
(ii) the allele frequency after its distortion through amplification bias. For a site
with total coverage of l reads, of which k reads bear the alternative allele, the
formal definition of this measurable frequency is ρs ¼ kl .
The goal is to estimate the likelihood density across the three possible
underlying allele frequencies in the single-cell (we denote ~θs as the density estimate
across all θs∈ {0.0, 0.5, 1.0}). To accurately quantify the uncertainty introduced by
amplification bias, we consider
PðρsjθsÞ for θs 2 f0; 0:5; 1g; ð1Þ
the probability distributions that reflect the shift from the true allele frequency θs to
the distorted allele frequency ρs, as induced by MDA (Fig. 3c). We thus formally
describe the statistics of read counts skewed by MDA at all sites, encompassing
sites that are homozygous for the reference allele, heterozygous, or homozygous for
the alternative allele, to calculate likelihoods for each of these possible true allele
frequencies.
To do this, we follow the considerations of Lodato et al.22 (see Fig. S5 and the
section “Modeling MDA-derived alternative read counts” of the respective
supplement for the details), who fitted well-studied probability distributions to
empirical distributions they obtained for P(ρs∣θs) of θs∈ {0, 0.5}. For sites that are
homozygous for the reference allele, amplification bias cannot initially happen.
However, once an amplification error creates an alternative allele, this can be
amplified to large frequencies due to amplification bias. Lodato et al.22 thus
consider the empirical distribution P(ρs∣θs= 0) to follow a beta-binomial.
Effectively, this means that the probability of a nonzero alternative read count
(ρs > 0, which is an alternative read count above 0 in Fig. 3a) will be nonzero
(P(ρs∣θs= 0) > 0), merely because of sequencing and amplification errors. In
contrast, at heterozygous sites (Fig. 3b), the distribution is dominated by
amplification bias. Thus, for P(ρs∣θs= 0.5) they found a mixture of two beta-
binomial distributions to appropriately fit the empirically observed distributions
(Fig. 3b). We further motivate the choice of the beta-binomial distribution
mechanistically by an analogy to its generative urn model named after Pólya43:
Take an urn with two white and two black balls, where each ball represents one
strand of each (double-stranded) allele at a heterozygous site. In the Pólya urn
model, drawing a ball leads to the replacement of that ball with two balls of the
same color, analogous to a strand copy by the Φ29 polymerase (additional
discussion in the Supplement, Supplementary Section 1.2.1). Finally, the necessity
for a mixture of beta-binomials (Fig. 3b) becomes evident when contrasting it with
the binomial distribution observed at heterozygous sites in bulk experiments.
Namely, the bulk distribution for reads supporting the alternative allele would
narrowly peak at a count of k ¼ l2, which is not the case for the corresponding
k= 10 in Fig. 3b. Instead, the mixture of beta-binomials peaks at the extreme read
counts of k= 0 and k= l, highlighting that the dropout of the alternative or
reference allele is quite likely to occur. Most likely, this mixture arises from
differences in the accessibility of different pieces of the genomic DNA for
amplification25 (Supplement, Supplementary Section 1.2.1). Finally, for
homozygous alternative sites (i.e., P(ρs∣θs= 1)), we rely on the symmetry of the











Þ ¼ wðlÞ ´BBð k; l; α1ðlÞ; α1ðlÞ Þ




jθs ¼ 1Þ ¼ BBð k; l; βðlÞ; αðlÞ Þ:
ð2Þ
Here, BB represents the beta-binomial probability mass function where k∈ {0,
..., l} with l being the total read coverage of the site that is considered. All of
parameters α, α1, α2, β, and w scale linearly in l. Allowing to vary distributions
through these parameters allows amplification bias to depend on the total coverage
of a site, and thereby to vary locally. The symmetry of distributions for the
homozygous sites (θs= 0 in Fig. 3a, and θs= 1) is established by swapping the
shape parameters α(l) and β(l). The distribution for heterozygous sites (Fig. 3b)
corresponds to a mixture of two beta-binomials with shape parameters α1(l)= β2(l)
and α2(l)= β2(l), where equality of α(l) and β(l) yields symmetry of the
distributions relative to k ¼ l2 (the expected value for alternative read counts at
heterozygous sites). Slopes and intersects for the scaling of all parameter values
across different choices of l are given in Table 1.
Using bulk evidence of alternative alleles to increase the accuracy of variant calls. A
bulk sequencing sample of the same cell type from the same organism is a much
larger sampling of that cell population than the sequencing of dozens of single cells.
Unless a single cell is the only one to harbor a particular mutation, a deep enough
sequencing of the bulk sample from which the single cell was drawn should contain
reads from cells that share the particular mutation with the single cell. Thus,
considering bulk samples corresponds to drawing unbiased samples of the entire
population (of genome copies), in contrast to single cells that correspond to heavily
distorted measurements on pairs of copies. This establishes a formal, statistical
argument why one should consider bulk experiments in single-cell sequencing
whenever possible: the identification of a mutation in an accompanying bulk
sample lends further credibility to the mutation in the single cell, in a data-driven
way, without assuming any fixed error rate (Fig. 3c). At the same time, the absence
of a single cell candidate mutation in a bulk sample (with sufficient sequencing
depth) increases the probability of an amplification error. As a consequence, bulk
samples can be employed to improve both the sensitivity and specificity of variant
calls in the single cell, where the increasing depth of coverage of the bulk sample
increases the accuracy of the calls.
For our model, we derive likelihood density estimates for all possible alternative
allele frequencies in the background bulk sample. Given a set of n reads from the
bulk (b) read data Zb ¼ fZb1;Zb2; ¼ ;Zbng, and discrete possible allele frequencies mn
(m∈ 0, 1, …, n), we compute the probability of the data given a particular allele


















Here, the probability of an individual read, given a particular allele frequency,
PðZbj jθb ¼ mnÞ, is defined as in Supplementary Equation S 21, based on the model
described in Köster et al.31. Further, as for the single-cell sample, when referring to
the likelihood density estimates across all possible allele frequencies (as opposed to
a particular allele frequency), we denote this with ~θb .
Calculating posterior probabilities for events at single-cell sites, including a bulk
background sample. With single-cell genotype likelihoods adjusted by our empirical
amplification bias model (Eq. (2)) and auxiliary evidence on alternative alleles from
a bulk sample (Eq. (3)), we define mutually exclusive single-cell events. Figure 3c
gives a simplified illustration of how the combination of likelihood density esti-
mates across all possible allele frequencies ~θs and ~θb works for calling a hetero-
zygous and a homozygous genotype in a single cell. However, our model fully
defines the two-dimensional space of possible underlying alternative allele fre-
quencies in the two samples as:





´ ½0; 1~θb : ð4Þ
For these definitions, we always assume that—regarding a particular genomic
site—the bulk cell population can only consist of a maximum of two
subpopulations that are exactly one mutated allele apart from each other (Fig. 3d,
lower panel; for discussion on the validity of this assumption, see Supplementary
Section 1.5.1). At allele frequencies θb∈ {0, 0.5, 1}, we assume a homogeneous
population of only homozygous reference, heterozygous, or homozygous
alternative cells, respectively. At frequencies in between, we assume a mixture of
heterozygous cells with homozygous reference cells (θb∈ (0, 0.5)), or with
homozygous alternative cells (θb∈ (0.5, 1)). Bearing this assumption in mind, we
define single-cell events as mutually exclusive two-dimensional sub-spaces. For
Table 1 Parameters of the multiple displacement
amplification (MDA) amplification bias model as presented







The full precision as used in the implementation is given in Supplementary Supplementary
Table 1.
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example, an error-free homozygous alternative site is defined by allele frequency





. And the dropout of
an alternative allele is defined across allele frequency likelihood density estimates





(Fig. 3d and Supplementary Table 2). For the latter,
please note that we here resolve a contradiction between ~θs ¼ 0, which indicates a
homozygous reference single cell, and ~θb 2 ½0:5; 1Þ, which indicates that the bulk
does not contain any homozygous reference cells. We decide to trust the bulk
sample over the single-cell sample, and with our above assumption that the bulk is
a mixture of a maximum of two subpopulations, the bulk can only contain
heterozygous and homozygous alternative cells. This renders a homozygous
reference single-cell impossible, and we classify this event as evidence for an allele
dropout of the alternative allele.
We thus obtain a set of mutually exclusive single-cell events (Fig. 3d):
E ¼ fEhom ref ; Eerr alt; EADO to alt; Ehet; EADO to ref ; Eerr ref ; Ehom altg
ð5Þ
Assuming a flat prior across the possible underlying allele frequencies for both
the bulk and the single cell, we can compute likelihoods for all those single-cell
events (e.g., Supplementary Equation S 28). The sum of the likelihoods of all these
(mutually exclusive) events yields the marginal probability (Supplementary
Equation S 26). Using the marginal probability, we can calculate the posterior
probability for any of these events. For example, the posterior probability of event












Accounting for the sample likelihoods based on Supplementary Equation S 23
(assuming ρb= θb for the bulk that has no amplification step, Supplementary
Equation S 3), and evaluating only point estimates of these likelihoods at possible























Accounting for amplification bias with Eq. (2) and computing the likelihood of
the sample-specific allele frequency ranges with Supplementary Equation S 22 and
























With read probabilities calculated with Supplementary Equation S 21, we can
calculate the posterior probability of the Ehom alt event (for an analogous and more
detailed derivation for EADO to ref, see Supplement, Supplementary Section 1.4). To
obtain posterior probabilities for compound events, we sum up the posterior
probabilities of the events it comprises, effectively joining up their respective allele
frequency range combinations into compound range combinations. For the site-
specific single-cell probability for the presence of an alternative allele in the single
cell, we thus get the compound event (blue events in Fig. 3d and Supplementary
Table 2):
Ealt presences











































´ 0; 1ð θb
ð9Þ
whose posterior probability we can obtain from this sum:
Pðalt presencesjZs;ZbÞ ¼PðEADO to ref jZs;ZbÞ þ PðEerr ref jZs;ZbÞ þ PðEhetjZs;ZbÞ
þ PðEADO to altjZs;ZbÞ þ PðEhom altjZs;ZbÞ
ð10Þ
To genotype, we calculate the posterior probability of all three possible single-
cell genotypes and choose the genotype with the maximum posterior probability. In
Fig. 3d, events are colored purple when implying the homozygous reference
genotype, light blue when implying the heterozygous genotype, and dark blue when
implying the homozygous alternative genotype (Supplementary Table 2). Similarly,
to calculate the posterior probability of an allele dropout at a particular site, we sum
up the posterior probabilities of the two ADO events.
For any such compound event, we can estimate a threshold on the posterior
probabilities that controls for a specified false discovery rate. This is based on the
approach described by Müller et al.44—for further details see the Supplement
(Sections S 1.6 and Supplementary Fig. 2.6) and Köster et al.31.
Biologically relevant imputation based on the bulk sample. As argued above, a large
enough sampling of the bulk cell population that the single-cell comes from should
contain the single cell’s genotype at a particular site, unless this cell is genuinely the
first cell to harbor a mutation at that site. This bulk background sample can thereby
render credibility to single-cell variants with low coverage, while at the same time
eliminating amplification errors in the single-cell sample, as these will not exist in
the bulk sample. Interestingly, the bulk sample also provides a mechanism of
biologically meaningful imputation at sites that have no read coverage in the single
cell. If imputation is desired for sites with no read coverage in the single cell, we set
PðZsjθs ¼ 0Þ ¼ PðZsjθs ¼ 12Þ ¼ PðZsjθs ¼ 1Þ ¼ 1, rendering all (unknown under-
lying) single-cell genotypes equally likely. Thus, the posterior probabilities of events
at sites with no read coverage become solely dependent on the read data from the
bulk sample, providing the most common genotype in the bulk. However, while
this is a biologically meaningful way of imputation at the vast majority of genomic
sites, it should be noted that this imputation will favor germline genotypes over any
existing (lower frequency) somatic genotypes at a site, unless such a somatic
genotype is present in a majority of cells. Thus, such an imputation carries the
potential to introduce erroneous calls (especially when looking at subclonal somatic
mutations), and we recommend to instead use downstream tools that can
accommodate for missing data and data uncertainty wherever they are available.
ProSolo is an easy-to-use command-line tool, based on a modular framework.
ProSolo is an easy-to-use command-line tool—following usability standards45—
and its source code is available at https://github.com/prosolo/prosolo, including
instructions for an easy installation via Bioconda46. Its main contribution in terms
of software is the implementation of its comprehensive statistical model into the
Rust variant calling library of Varlociraptor31. See Supplement (Supplementary
Section 1.6) for further implementation details.
Benchmarking. We compare ProSolo to the state-of-the-art for SNV calling from
single-cell sequencing data of multiple displacements amplified (MDA) DNA:
MonoVar27, SCAN-SNV30, SCcaller28, and SCIPhI29. We used Snakemake47
(version 6.3.0) to implement the benchmarking workflows. For detailed informa-
tion on benchmarking setup and results, see Supplementary Supplementary Sec-
tion 2. All code used for benchmarking is available at: https://github.com/prosolo/
benchmarking_prosolo(or as preserved by Zenodo at: https://doi.org/10.5281/
zenodo.3769115).
Datasets and ground truths. We benchmarked ProSolo on three experimental
datasets (Fig. 4), each with a different kind of ground truth:
Whole genome sequencing of almost identical kin-cells from a cell line28. The
first dataset comes from the publication of the SCcaller software28 (Fig. 4a, dataset
available from SRA project PRJNA305211 [https://www.ncbi.nlm.nih.gov/sra/?
term=PRJNA305211], accessions SRR2976561 to SRR2976566). A single starting
cell was grown in two steps (Fig. 1 of the original paper28): After an initial mini-
expansion, a single cell was selected as the founder for the secondary IL expansion
into 20–30 cells. From this, two cells were extracted (IL-11 and IL-12) and
sequenced following MDA. The remaining kindred cells from that clone were used
as a bulk sequencing sample without amplification (IL-1C). IL-1C serves as the
ground truth, as these cells are only very few cell divisions away from IL-11 and IL-
12, and thus have almost no difference in the somatic mutations acquired. The
ground truth genotype was generated using GATK HaplotypeCaller to call variant
sites and bcftools mpileup to identify homozygous reference sites (with read
coverage above 25 but no alternative allele present). IL-1C was only used as ground
truth and not provided as input to any of the software compared here. Three more
distant clones (C1, C2, C3), generated from cells after the first mini-expansion,
were merged into a further bulk sample for SCcaller and ProSolo (see Software and
Parameters below). Unlike other callers (all of which finished in less than 5 days),
SCIPhI took 5 weeks to finish on this dataset in sensitive mode and 7.5 weeks in
default mode.
Whole exome sequencing of five human granulocytes with a pedigree ground
truth. For the second benchmarking dataset, blood was taken from a patient with a
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constitutional mismatch repair-deficiency48 after informed consent. Data
acquisition protocols were approved by the Ethics Committee of the Medical
Faculty of the Heinrich Heine University Düsseldorf. Granulocytes were selected
via magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting
(FACS, Fig. 4b, dataset available as EGAD00001005929 [https://ega-archive.org/
datasets/EGAD00001005929] in EGA study EGAS00001004123). Individual cells
were isolated using a microfluidics device and subjected to multiple displacement
amplification (MDA). Using a panel of 16 primer pairs covering different genes
across chromosomes (Supplementary Table 3) for quantitative real-time PCR, we
selected granulocytes where at least 15 of these loci were properly amplified. For
those cells, we performed whole-exome capture, sequencing library preparation,
and paired-end Illumina sequencing. From the remaining sorted cell population,
we also extracted bulk DNA and submitted it to whole-exome capture and paired-
end Illumina sequencing without MDA, to generate a bulk background sample for
ProSolo and SCcaller.
To generate the ground truth of this dataset, we could leverage previously
sequenced bulk whole-exome data from the same person, their parents, and three
siblings48 (Fig. 4b). To create ground truth germline alternative allele calls, we ran
three pedigree-aware variant callers (BEAGLE4.049, polymutt50, and FamSeq51,52)
and created a consensus by including only calls where all callers agree at a site and
where a maximum of one caller not calling the site was allowed (Supplementary
Fig. 5).
Single nucleus exome sequencing of 16 normal and 16 tumor cells from triple-
negative breast cancer (TNBC)21. The third dataset is a published dataset from a
TNBC patient, with both tumor and matched normal cells available (Fig. 4c,
dataset available via the sequence read archive, project id PRJNA168068 [https://
www.ncbi.nlm.nih.gov/sra/?term=PRJNA168068] or accession SRA053195). For
each, 16 single cell nuclei and a bulk sample were the whole-exome sequenced.
Further, a number of candidate sites for clonal and subclonal tumor mutations was
confirmed by targeted duplex deep sequencing in a separate experiment21. We
analyzed the tumor and normal cells separately, ensuring that normal cells were
called with the normal bulk background sample and tumor cells with the tumor
bulk background sample. As the ground truth for the tumor cells, we then used the
normal bulk sample augmented with the clonal tumor mutations confirmed by
targeted duplex sequencing. As the ground truth for the normal cells, we used the
tumor bulk sample, removing the confirmed clonal and subclonal tumor
mutations. This experimental setup aims for fairness across all competitors.
Variant calling for the ground truths was performed as for cell line data above.
Estimates of allele dropout rate validate ProSolo’s model. For the allele dropout rate,
we will focus on the set of sites where the respective ground truth call is hetero-
zygous, as these are the sites where the dropout of one of the alleles can be
identified in a nonambiguous manner. More details for the three ways in which we
calculate allele dropout rates are given in Supplement (Supplementary Section 2.7).
Here, we give a short explanation:
1. At each ground truth heterozygous site, we sum the posterior probabilities
of the two allele dropout events defined in ProSolo (“ADO to alt” and “ADO
to ref” in Fig. 3d) to obtain a total allele dropout probability (Supplementary
Equation S 31) and use these to compute the expected value of allele dropout
across all sites. This gives us an expected allele dropout rate (“expected
value” in Fig. 2, Supplementary Equation S 33).
2. We genotype all the ground truth heterozygous sites with ProSolo, take the
most likely genotype, and then compare against the ground truth:
heterozygous sites that ProSolo calls homozygous are counted as dropout
sites. The number of such sites is divided by the total number of ground
truth heterozygous sites where the respective single cell had coverage (“hom
at ground truth het” in Fig. 2 and Supplementary Equation S 34).
3. We identify all heterozygous ground truth sites with a coverage of at least 7,
where without amplification bias we could be reasonably sure to sample
both alleles (for the reasoning see Supplement, Supplementary Section 2.7).
We then count a site as an allele dropout if there is one allele (reference or
alternative) with no read coverage at all, and again divide by the total
number of ground truth heterozygous sites where the respective single cell
had coverage (“no alt/ref read at ground truth het” in Fig. 2 and
Supplementary Equation S 35).
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Lists of accessions for all samples used are given in the accompanying GitHub repository,
namely at: https://github.com/ProSolo/benchmarking_prosolo/tree/v5.0/analysis_
pipelines#dataset. This repository is also archived via Zenodo: https://doi.org/10.5281/
zenodo.3769115. Dong et al. (2017)28 provide the first dataset (Fig. 4a) via the Sequence
Read Archive as SRA project PRJNA305211 (accessions SRR2976561 to SRR2976566):
https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA305211. We provide the second
dataset alongside this publication (Fig. 4b) via the European Genome-Phenome Archive as
EGA dataset EGAD00001005929: https://ega-archive.org/datasets/EGAD00001005929. As
this is patient data, interested researchers need to contact the data access committee of this
dataset via the EGA platform and sign a license agreement to gain data access: https://ega-
archive.org/dacs/EGAC00001001468. Wang et al. (2014)21 provide the third dataset
(Fig. 4c) via the Sequence Read Archive as SRA project PRJNA168068 (accession
SRA053195): https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA168068.
Code availability
All code used in data analysis and preparation of the manuscript, alongside a description
of necessary steps for reproducing results, can be found in a GitHub repository
accompanying this manuscript: https://github.com/prosolo/benchmarking_prosolo. To
ensure its long-term availability and make it citable, we have created a release of this
repository and archived it on Zenodo: https://doi.org/10.5281/zenodo.3769115. Further,
the code of ProSolo itself is in the following GitHub repository: https://github.com/
prosolo/prosolo. The version of the code used in this study has been archived under:
https://doi.org/10.5281/zenodo.5366555.
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